China growth levels are the thorn in Coloplast's side, CEO reveals
The hard-line Covid-19 policy in China means lower activity and growth levels, and that is a problem for the medtech firm, which has a large market share in the country.
by marketwire, translated by catherine brett
Several markets are normalizing for Coloplast after the Covid-19 pandemic, but in China, the disease is still causing problems for the medtech firm, CEO Kristian Villumsen tells MarketWire.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Coloplast raises prices to offset energy cost spikes
For subscribers
